

# Vincenzo Mazzaferro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4317462/publications.pdf>

Version: 2024-02-01

334  
papers

66,702  
citations

4103

90  
h-index

867

250  
g-index

336  
all docs

336  
docs citations

336  
times ranked

43034  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	6.1	90
2	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	6.1	42
3	The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review. <i>European Journal of Surgical Oncology</i> , 2022, 48, 150-159.	0.5	19
4	Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry. <i>Updates in Surgery</i> , 2022, 74, 87-96.	0.9	10
5	Pancreaticoduodenectomy in octogenarians: The importance of "biological age" on clinical outcomes. <i>Surgical Oncology</i> , 2022, 40, 101688.	0.8	7
6	Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 54-61.	0.9	0
7	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
8	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	12.5	643
9	The EASL "Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116.	6.3	257
10	Impact of Surgical Margins on Overall Survival after Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series. <i>Annals of Surgical Oncology</i> , 2022, 29, 3096-3108.	0.7	10
11	ASO Visual Abstract: Impact of Surgical Margins on Overall Survival After Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series. <i>Annals of Surgical Oncology</i> , 2022, 29, 3111.	0.7	1
12	Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods. <i>Cancers</i> , 2022, 14, 959.	1.7	11
13	Migration rate using Fully-covered metal stent in anastomotic strictures after liver transplantation: Results from the BASALT Study Group. <i>Liver International</i> , 2022, , .	1.9	3
14	ASO Author Reflections: Less is more: Organ-Sparing Approach for the Surgical Treatment of Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 3109-3110.	0.7	1
15	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100472.	1.5	2
16	Variations in risk-adjusted outcomes following 4318 laparoscopic liver resections. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 521-530.	1.4	6
17	Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. <i>Cancers</i> , 2022, 14, 69.	1.7	9
18	MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers. <i>Molecular Oncology</i> , 2022, 16, 2733-2746.	2.1	2

#	ARTICLE	IF	CITATIONS
19	Utility of the Iwate difficulty scoring system for laparoscopic right posterior sectionectomy: do surgical outcomes differ for tumors in segments VI and VII?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 9204-9214.	1.3	3
20	DNA Methylation Profiling of Human Hepatocarcinogenesis. <i>Hepatology</i> , 2021, 74, 183-199.	3.6	42
21	Preoperative predictors of liver decompensation after mini-invasive liver resection. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 718-727.	1.3	10
22	Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study. <i>British Journal of Surgery</i> , 2021, 108, 196-204.	0.1	76
23	ASO Author Reflections: Amid Anatomic Restrictions, Three-Dimensional Surgical Planning Eases En Bloc Resection of the Retro-Hepatic Vena Cava and the Caudate Lobe of the Liver. <i>Annals of Surgical Oncology</i> , 2021, 28, 6850-6851.	0.7	0
24	Resection of Retro-Hepatic Vena Cava (RHVC) En-bloc with Caudate Lobe without Vascular Exclusion for a Low Grade Leiomyosarcoma of Inferior Vena Cava. <i>Annals of Surgical Oncology</i> , 2021, 28, 6848-6849.	0.7	3
25	Liver resection for perihilar cholangiocarcinoma: Impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study. <i>Surgery</i> , 2021, 170, 383-389.	1.0	10
26	Improved management of grade B biliary leaks after complex liver resections using gadoxetic acid disodium-enhanced magnetic resonance cholangiography. <i>Surgery</i> , 2021, 170, 499-506.	1.0	2
27	Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors. <i>Transplantation</i> , 2021, 105, 2579-2586.	0.5	13
28	The Italian Consensus on minimally invasive simultaneous resections for synchronous liver metastasis and primary colorectal cancer: A Delphi methodology. <i>Updates in Surgery</i> , 2021, 73, 1247-1265.	0.9	33
29	Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 8903-8912.	2.3	3
30	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	1.3	19
31	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
32	Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation. <i>Nanotheranostics</i> , 2021, 5, 1-7.	2.7	13
33	Transplant Oncology in Primary and Metastatic Liver Tumors. <i>Annals of Surgery</i> , 2021, 273, 483-493.	2.1	33
34	Quantitative assessment of the impact of COVID-19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1423 cases from 10 tertiary referral centers. <i>Updates in Surgery</i> , 2021, , 1.	0.9	6
35	Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 75-84.	1.8	105
36	Surgical Management of Hepatic Benign Disease: Have the Number of Liver Resections Increased in the Era of Minimally Invasive Approach? Analysis from the I Go MILS (Italian Group of Minimally Invasive) Tj ETQq0 0 0 r9BT /Overlock 10 Tf 5		

#	ARTICLE	IF	CITATIONS
37	Risk-adjusted benchmarks in laparoscopic liver surgery in a national cohort. <i>British Journal of Surgery</i> , 2020, 107, 845-853.	0.1	29
38	Multicentre evaluation of case volume in minimally invasive hepatectomy. <i>British Journal of Surgery</i> , 2020, 107, 443-451.	0.1	18
39	The chances of hepatic resection curing hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 711-717.	1.8	41
40	Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2020, 8, 140-147.	1.6	17
41	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. <i>Annals of Surgery</i> , 2020, 272, 855-862.	2.1	85
42	A Combined Approach to Priorities of Surgical Oncology During the COVID-19 Epidemic. <i>Annals of Surgery</i> , 2020, 272, e84-e86.	2.1	16
43	Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi-center retrospective cohort study. <i>Transplant International</i> , 2020, 33, 567-575.	0.8	44
44	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6350-6361.	3.2	35
45	Minimally Invasive Stage 1 to Protect Against the Risk of Liver Failure: Results from the Hepatocellular Carcinoma Series of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Italian Registry. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2020, 30, 1082-1089.	0.5	13
46	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Retransplant. <i>JAMA Surgery</i> , 2020, 155, e204095.	2.2	67
47	Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry. <i>Liver Cancer</i> , 2020, 9, 455-467.	4.2	8
48	Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward. <i>Lancet Oncology</i> , The, 2020, 21, 740-741.	5.1	8
49	Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3018-3032.	3.3	44
50	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	5.1	166
51	Liver resection and transplantation for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 72, 364-377.	1.8	177
52	COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 532-533.	3.7	217
53	Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. <i>Journal of Hepatology</i> , 2020, 73, 342-348.	1.8	49
54	HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post-hoc analysis. <i>Transplant International</i> , 2020, 33, 917-924.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	1.0	16
56	Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1136-1142.	0.5	105
57	Liver transplantation as last-resort treatment for patients with bile duct injuries following cholecystectomy: a multicenter analysis. <i>Annals of Gastroenterology</i> , 2020, 34, 111-118.	0.4	1
58	Liver Resection and Transplantation for Metastases from Gastroenteropancreatic Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2020, , 221-233.	0.0	0
59	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019, 68, 1065-1075.	6.1	195
60	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. <i>British Journal of Cancer</i> , 2019, 121, 340-343.	2.9	62
61	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. <i>American Journal of Pathology</i> , 2019, 189, 2090-2101.	1.9	17
62	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	2.6	60
63	Comparison Between Swan-Ganz Catheter and Minimally Invasive Hemodynamic Monitoring During Liver Transplantation: Report of a Monocentric Case Series. <i>Transplantation Proceedings</i> , 2019, 51, 2943-2947.	0.3	3
64	Heterologous and cross-species tropism of cancer-derived extracellular vesicles. <i>Theranostics</i> , 2019, 9, 5681-5693.	4.6	48
65	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 217-226.	1.3	29
66	Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1001-1007.	1.1	11
67	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	0.6	7
68	A national mandatory-split liver policy: A report from the Italian experience. <i>American Journal of Transplantation</i> , 2019, 19, 2029-2043.	2.6	52
69	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1696-1707.	7.7	157
70	Permanent Pancreatic Duct Occlusion With Neoprene-based Glue Injection After Pancreatoduodenectomy at High Risk of Pancreatic Fistula. <i>Annals of Surgery</i> , 2019, 270, 791-798.	2.1	25
71	Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver) Tj ETQq1 1 0.784314 argBT / Overlock 10	1.4	10
72	Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. <i>Journal of Controlled Release</i> , 2019, 294, 165-175.	4.8	93

#	ARTICLE	IF	CITATIONS
73	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	1.0	7
74	Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. <i>Hpb</i> , 2019, 21, 731-738.	0.1	24
75	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171.	2.9	279
76	Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection. <i>European Journal of Surgical Oncology</i> , 2019, 45, 755-760.	0.5	14
77	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	2.3	20
78	Endo-therapies for biliary duct-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey. <i>Liver International</i> , 2019, 39, 1355-1362.	1.9	18
79	Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. <i>Gut</i> , 2019, 68, 130-139.	6.1	150
80	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 107-120.	3.6	433
81	pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. <i>Oncimmunology</i> , 2018, 7, e1445452.	2.1	54
82	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	5.1	285
83	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	1.8	6,153
84	Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. <i>Hpb</i> , 2018, 20, 768-775.	0.1	44
85	Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. <i>Transplant International</i> , 2018, 31, 531-539.	0.8	41
86	Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better. <i>Hepatology</i> , 2018, 68, 775-777.	3.6	8
87	Relative Survival Instead of Overall Survival Should Be Used as Outcome When Analyzing the Effect of Age After Treatment of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2018, 268, e76.	2.1	0
88	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. <i>Journal of Hepatology</i> , 2018, 68, 724-732.	1.8	100
89	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
90	Reply to: "Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion". <i>Journal of Hepatology</i> , 2018, 69, 260-261.	1.8	1

#	ARTICLE	IF	CITATIONS
91	Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. <i>Journal of the American College of Surgeons</i> , 2018, 226, 1147-1159.	0.2	13
92	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	2.9	17
93	Pro (With Caution): Extended oncologic indications in liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 98-103.	1.3	24
94	Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 154, 128-139.	0.6	417
95	85. Treatment of hepatocarcinoma with 90Y glass microspheres: Safety and indication of prolonged overall survival thanks to two compartment dosimetric treatment planning. <i>Physica Medica</i> , 2018, 56, 114-115.	0.4	0
96	The SIRveNIB and SARA trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 487-489.	0.7	39
97	Hepatocellular Carcinoma in Abernethy Malformation: A Rare Occurrence of Congenital Complete Portosystemic Shunt. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1775-1778.	0.2	3
98	Systemic Administration and Targeted Delivery of Immunogenic Oncolytic Adenovirus Encapsulated in Extracellular Vesicles for Cancer Therapies. <i>Viruses</i> , 2018, 10, 558.	1.5	73
99	Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2018, 268, 868-875.	2.1	127
100	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2018, 69, 1284-1293.	1.8	360
101	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	3.2	63
102	Clinical Options for Treatment of Hepatocellular Carcinoma. , 2018, , 95-105.		0
103	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. <i>BMC Cancer</i> , 2018, 18, 715.	1.1	15
104	A Longitudinal Investigation of Posttraumatic Growth and Quality of Life in Liver Transplant Recipients. <i>Progress in Transplantation</i> , 2018, 28, 236-243.	0.4	12
105	Reply. <i>Gastroenterology</i> , 2018, 154, 2276-2277.	0.6	1
106	Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017, 67, 415-417.	1.8	7
107	Hepatic Epithelioid Hemangi endothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry. <i>Transplantation</i> , 2017, 101, 555-564.	0.5	75
108	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017, 153, 812-826.	0.6	650

#	ARTICLE	IF	CITATIONS
109	Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey. <i>Liver Transplantation</i> , 2017, 23, 257-261.	1.3	16
110	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. <i>Endocrine</i> , 2017, 57, 512-517.	1.1	8
111	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
112	Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. <i>European Journal of Surgical Oncology</i> , 2017, 43, 380-387.	0.5	51
113	A matched pair analysis of multicenter longterm followup after splitliver transplantation with extended right grafts. <i>Liver Transplantation</i> , 2017, 23, 1384-1395.	1.3	21
114	Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1704-1712.	0.1	21
115	Donor safety in living donor liver donation: An Italian multicenter survey. <i>Liver Transplantation</i> , 2017, 23, 184-193.	1.3	55
116	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	1.0	12
117	Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from preto postliver transplant: a real-life strategy. <i>Liver International</i> , 2017, 37, 678-683.	1.9	10
118	The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 473-483.	2.6	26
119	Thrombosis after liver transplantation for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0186699.	1.1	8
120	Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma. <i>World Journal of Radiology</i> , 2017, 9, 245.	0.5	25
121	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	1.1	56
122	Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: A multicentre randomised clinical trial. <i>European Journal of Cancer</i> , 2016, 64, 107-112.	1.3	60
123	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016, 16, 2892-2902.	2.6	151
124	Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, 871-880.	0.1	130
125	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1033-1042.	1.9	28
126	Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 645-653.	1.4	71



#	ARTICLE	IF	CITATIONS
127	External validation of an individual prognostic calculator after transarterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1231-1231.	1.9	4
128	Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. <i>Hepatology</i> , 2016, 63, 1707-1717.	3.6	110
129	Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012-2014. <i>Hpb</i> , 2016, 18, 419-427.	0.1	56
130	Endoscopic ultrasound-guided esophagoenterostomy for a completely obstructed surgical anastomosis. <i>Endoscopy</i> , 2016, 48, E1-E2.	1.0	24
131	Endoscopic ultrasound-guided fine needle aspiration of splenic vein thrombosis: a novel approach to the portal venous system. <i>Endoscopy</i> , 2016, 48, E40-E41.	1.0	4
132	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. <i>Future Oncology</i> , 2016, 12, 1251-1260.	1.1	29
133	Liver transplantation for "every early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. <i>Hepatology</i> , 2016, 64, 1178-1188.	3.6	262
134	Effect of age on survival in patients undergoing resection of hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, e93-e99.	0.1	53
135	Liver transplantation for adenomatosis: European experience. <i>Liver Transplantation</i> , 2016, 22, 516-526.	1.3	41
136	Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 846.	2.2	106
137	Expert opinion on advanced techniques for hemostasis in liver surgery. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1597-1607.	0.5	8
138	Reply. <i>Hepatology</i> , 2016, 63, 1054-1055.	3.6	2
139	Surgical management of duodenal stump fistula after elective gastrectomy for malignancy: an Italian retrospective multicenter study. <i>Gastric Cancer</i> , 2016, 19, 273-279.	2.7	24
140	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2016, 100, 116-125.	0.5	339
141	Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 291-300.	3.2	185
142	Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. <i>PLoS ONE</i> , 2016, 11, e0156127.	1.1	70
143	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. <i>Oncotarget</i> , 2016, 7, 72343-72355.	0.8	57
144	Development of a prognostic scoring system for resectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8194.	1.4	7

#	ARTICLE	IF	CITATIONS
145	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2187-2193.	1.9	2
146	Dissecting EASL/AASLD Recommendations With a More Careful Knife. <i>Annals of Surgery</i> , 2015, 262, e17-e18.	2.1	16
147	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015, 32, 182.	1.2	22
148	A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a Blended Principle Model. <i>American Journal of Transplantation</i> , 2015, 15, 2552-2561.	2.6	164
149	Authors' response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al. <i>Gut</i> , 2015, 64, 522-522.	6.1	5
150	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	5.8	240
151	DNA methylation-based prognosis and epdrivers in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	3.6	367
152	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	0.6	109
153	Repeated transarterial chemoembolization: An overfitting effort?. <i>Journal of Hepatology</i> , 2015, 62, 1440-1442.	1.8	18
154	Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1368-1377.	1.8	64
155	Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1718-1738.	3.3	128
156	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. <i>Future Oncology</i> , 2015, 11, 1947-1959.	1.1	9
157	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , 2015, 62, S144-S156.	1.8	239
158	Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing. <i>Hepatology</i> , 2015, 62, 340-342.	3.6	22
159	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	9.4	1,372
160	Liver transplantation for neuroendocrine tumour liver metastases. <i>Hpb</i> , 2015, 17, 23-28.	0.1	78
161	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1344-1354.	5.1	809
162	When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. <i>Hpb</i> , 2015, 17, 17-22.	0.1	59

#	ARTICLE	IF	CITATIONS
163	Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinicalâ€“Radiological Outcomes and Safety Profile. CardioVascular and Interventional Radiology, 2015, 38, 129-134.	0.9	59
164	Intrahepatic Flow Redistribution in Patients Treated with Radioembolization. CardioVascular and Interventional Radiology, 2015, 38, 322-328.	0.9	21
165	Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation. Seminars in Liver Disease, 2014, 34, 415-426.	1.8	60
166	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Annals of Oncology, 2014, 25, 1597-1603.	0.6	59
167	Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma. American Journal of Transplantation, 2014, 14, 2221-2227.	2.6	54
168	Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 223-230.	3.3	88
169	Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, 63, 844-855.	6.1	1,180
170	The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 634-638.	3.3	25
171	Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported <i>EWSR1</i> â€“ <i>FEV1</i> translocation. Histopathology, 2014, 64, 1014-1026.	1.6	19
172	Current challenges in liver transplantation for hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 867-879.	1.0	30
173	Reply to: â€œTime is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinomaâ€œ. Journal of Hepatology, 2014, 60, 230-231.	1.8	0
174	Reply to: â€œSorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issueâ€œ. Journal of Hepatology, 2014, 60, 682-683.	1.8	1
175	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. Digestive and Liver Disease, 2014, 46, 340-347.	0.4	18
176	Thoracic paravertebral anesthesia for percutaneous radiofrequency ablation of hepatic tumors. Journal of Clinical Anesthesia, 2014, 26, 271-275.	0.7	20
177	A Prospective Policy Development to Increase Split-Liver Transplantation for 2 Adult Recipients. Annals of Surgery, 2014, 259, 157-165.	2.1	53
178	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. European Journal of Cancer, 2013, 49, 3412-3419.	1.3	218
179	Transhepatic anterior approach to the inferior vena cava in large retroperitoneal tumors resected en bloc with the right liver lobe. Surgery, 2013, 154, 1061-1068.	1.0	10
180	Multiagent imaging of liver tumors with reference to intra-arterial radioembolization. Clinical and Translational Imaging, 2013, 1, 423-432.	1.1	3

#	ARTICLE	IF	CITATIONS
181	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study. <i>Journal of Hepatology</i> , 2013, 59, 59-66.	1.8	128
182	Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an Italian Center. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 484-488.	0.9	41
183	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. <i>Gastroenterology</i> , 2013, 144, 829-840.	0.6	438
184	Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. <i>Hepatology</i> , 2013, 58, 2188-2197.	3.6	154
185	Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. <i>Hepatology</i> , 2013, 57, 1826-1837.	3.6	428
186	Resection of hepatocellular cancer $\leq 2$ cm: Results from two Western centers. <i>Hepatology</i> , 2013, 57, 1426-1435.	3.6	326
187	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	1.8	508
188	Reply:. <i>Hepatology</i> , 2013, 58, 452-453.	3.6	0
189	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. <i>Tumori</i> , 2013, 99, e148-51.	0.6	4
190	Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum. <i>Cancers</i> , 2012, 4, 808-820.	1.7	6
191	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 173-185.	1.4	57
192	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	3.2	251
193	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 908-943.	1.8	5,214
194	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. <i>Journal of Hepatology</i> , 2012, 56, 1080-1088.	1.8	109
195	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012, 57, 297-305.	1.8	49
196	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	1.8	736
197	Liver Replantation in Adults: The Largest Multicenter Italian Study. <i>PLoS ONE</i> , 2012, 7, e46643.	1.1	22
198	A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with $^{90}\text{Y}$ glass microspheres. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 56, 503-8.	0.4	42

#	ARTICLE	IF	CITATIONS
199	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	0.6	389
200	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	0.6	205
201	Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor-recipient matching. <i>Digestive and Liver Disease</i> , 2011, 43, 155-164.	0.4	69
202	Importance of early nutritional screening in patients with gastric cancer. <i>British Journal of Nutrition</i> , 2011, 106, 1773-1778.	1.2	59
203	Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. <i>Cancer Treatment Reviews</i> , 2011, 37, 212-220.	3.4	460
204	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	1.8	133
205	Principles for the best multidisciplinary meetings. <i>Lancet Oncology</i> , The, 2011, 12, 323-325.	5.1	24
206	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 2724-2736.	2.6	86
207	Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. <i>Liver Transplantation</i> , 2011, 17, S44-S57.	1.3	471
208	Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: A review and consensus statement. <i>Liver Transplantation</i> , 2011, 17, S81-S89.	1.3	51
209	Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e21369.	1.1	56
210	Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 55, 168-97.	0.4	101
211	Simultaneous characterization of progenitor cell compartments in adult human liver. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2010, 77A, 31-40.	1.1	8
212	Duodenal Fistula after Elective Gastrectomy for Malignant Disease. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 805-811.	0.9	53
213	A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 190.	1.1	146
214	Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: Confirming the trial that will never be, and some comments on the indications for liver resection. <i>Hepatology</i> , 2010, 51, 1116-1118.	3.6	36
215	The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. <i>Transplant International</i> , 2010, 23, 712-722.	0.8	45
216	8. Multidisciplinary Approach for the Treatment of Neuroendocrine Tumors. <i>Tumori</i> , 2010, 96, 833-846.	0.6	24

#	ARTICLE	IF	CITATIONS
217	Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis. <i>PLoS Pathogens</i> , 2010, 6, e1000928.	2.1	145
218	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	1.8	211
219	Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle. <i>Journal of Hepatology</i> , 2010, 52, 771-775.	1.8	82
220	Exploiting liver immunity for the prevention of hepatic metastases. <i>Journal of Hepatology</i> , 2010, 53, 596-598.	1.8	2
221	miR-221 overexpression contributes to liver tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 264-269.	3.3	679
222	Multidisciplinary approach for the treatment of neuroendocrine tumors. <i>Tumori</i> , 2010, 96, 833-46.	0.6	12
223	CT cholangiography: Assessment of feasibility and diagnostic reliability. <i>European Journal of Radiology</i> , 2009, 72, 114-117.	1.2	10
224	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	1.8	206
225	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , The, 2009, 10, 35-43.	5.1	1,920
226	Milan criteria, up-to-seven criteria, and the illusion of a rescue package for patients with liver cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2009, 10, 208-209.	5.1	1
227	Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 1001-1007.	0.7	249
228	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
229	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1972-1983.e11.	0.6	644
230	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.4	589
231	Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2008, 653, 6-13.	0.9	50
232	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	13.9	1,148
233	Thyroid as a Target of Metastases. A Case of Foregut Neuroendocrine Carcinoma with Multiple Abdominal Metastases and a Thyroid Localization after 21 Years. <i>Tumori</i> , 2008, 94, 110-113.	0.6	17
234	The Place of Liver Transplantation in the Treatment of Hepatic Epitheloid Hemangioendothelioma. <i>Annals of Surgery</i> , 2007, 246, 949-957.	2.1	165

#	ARTICLE	IF	CITATIONS
235	Phenomenology and Emotional Impact of Neuropsychiatric Symptoms in Orthotopic Liver Transplant for Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2007, 39, 1564-1568.	0.3	3
236	First-Line Treatment for Hepatocellular Carcinoma: Resection or Transplantation?. <i>Transplantation Proceedings</i> , 2007, 39, 2271-2273.	0.3	15
237	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007, 46, 645-654.	1.8	75
238	Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation?. <i>Journal of Hepatology</i> , 2007, 47, 460-466.	1.8	290
239	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 938-947.	3.6	632
240	Results of liver transplantation: With or without milan criteria?. <i>Liver Transplantation</i> , 2007, 13, S44-S47.	1.3	66
241	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. <i>Gastroenterology</i> , 2006, 131, 1758-1767.	0.6	379
242	A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery. <i>Annals of Surgery</i> , 2006, 243, 89-95.	2.1	595
243	Transthyretin RNA profiling in livers from transplanted patients affected by familial amyloidotic polyneuropathy, and identification of a dual transcription start point. <i>Liver International</i> , 2006, 26, 211-220.	1.9	3
244	Percutaneous Transhepatic Biliary Drainage in the Management of Postsurgical Biliary Leaks in Patients with Nondilated Intrahepatic Bile Ducts. <i>CardioVascular and Interventional Radiology</i> , 2006, 29, 380-388.	0.9	66
245	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. <i>Hepatology</i> , 2006, 44, 1543-1554.	3.6	347
246	Split and whole liver transplantation outcomes: A comparative cohort study. <i>Liver Transplantation</i> , 2006, 12, 402-410.	1.3	106
247	Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: Questions, answers and demands for a common language. <i>Liver Transplantation</i> , 2006, 12, 896-898.	1.3	36
248	Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. <i>Liver Transplantation</i> , 2005, 11, 532-538.	1.3	78
249	Resection, transplantation, either, or both? Other pieces of the puzzle. <i>Liver Transplantation</i> , 2005, 11, 1177-1180.	1.3	16
250	ETOPOSIDE, CISPLATIN, EPIRUBICIN CHEMOTHERAPY IN THE TREATMENT OF PEDIATRIC LIVER TUMORS. <i>Pediatric Hematology and Oncology</i> , 2005, 22, 189-198.	0.3	6
251	Resection and Liver Transplantation for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 181-200.	1.8	1,043
252	Natural Killer and NK-Like T-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96. <i>Cancer Research</i> , 2005, 65, 3942-3949.	0.4	47

#	ARTICLE	IF	CITATIONS
253	Heat Shock Proteins and Their Use as Anticancer Vaccines. <i>Clinical Cancer Research</i> , 2004, 10, 8142-8146.	3.2	62
254	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 227-233.	2.0	116
255	94 Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary report. <i>Journal of Hepatology</i> , 2004, 40, 34.	1.8	4
256	Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation. <i>Annals of Surgery</i> , 2004, 240, 900-909.	2.1	452
257	Nonhepatic glucose production in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E129-E135.	1.8	64
258	<i>Helicobacter</i> species sequences in liver samples from patients with and without hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2004, 10, 598.	1.4	92
259	Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children. <i>Medical and Pediatric Oncology</i> , 2003, 41, 74-76.	1.0	35
260	Fibroblastic reticular cell tumor of the spleen: report of a case and review of the entity. <i>Human Pathology</i> , 2003, 34, 954-957.	1.1	38
261	Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells. <i>Journal of Immunology</i> , 2003, 171, 3467-3474.	0.4	116
262	Assessment of insulin sensitivity based on a fasting blood sample in men with liver cirrhosis before and after liver transplantation. <i>Transplantation</i> , 2003, 76, 697-702.	0.5	15
263	Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2003, 9, 3235-45.	3.2	197
264	Amino Acid Kinetics During the Anhepatic Phase of Liver Transplantation. <i>Diabetes</i> , 2002, 51, 1690-1698.	0.3	10
265	Candidates for liver transplantation for cancer: physical, psychological, and social conditions. <i>Transplantation</i> , 2002, 73, 1627-1635.	0.5	9
266	Feasibility of Peritonectomy Associated with Intraperitoneal Hyperthermic Perfusion in Patients with Pseudomyxoma Peritonei. <i>Tumori</i> , 2002, 88, 370-375.	0.6	17
267	Resting energy expenditure in diabetic and nondiabetic patients with liver cirrhosis: relation with insulin sensitivity and effect of liver transplantation and immunosuppressive therapy. <i>American Journal of Clinical Nutrition</i> , 2002, 76, 541-548.	2.2	41
268	Post-absorptive and insulin-mediated muscle protein metabolism in liver-transplanted patients. <i>Acta Diabetologica</i> , 2002, 39, 203-208.	1.2	6
269	Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. <i>Transplantation Proceedings</i> , 2001, 33, 1355-1357.	0.3	127
270	Liver transplantation for small hepatocellular carcinoma in cirrhosis: analysis of our experience. <i>Transplantation Proceedings</i> , 2001, 33, 1442-1444.	0.3	55



#	ARTICLE	IF	CITATIONS
271	Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation. Transplantation Proceedings, 2001, 33, 1516-1517.	0.3	54
272	Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplantation Proceedings, 2001, 33, 1537-1539.	0.3	93
273	Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel "hot spot"™ in codon 47. Clinical Genetics, 2001, 57, 284-290.	1.0	11
274	Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation. Hepatology, 2000, 31, 694-703.	3.6	114
275	Percutaneous Radio-frequency Thermal Ablation of Nonresectable Hepatocellular Carcinoma after Occlusion of Tumor Blood Supply. Radiology, 2000, 217, 119-126.	3.6	490
276	Effect of TT Virus Infection on Hepatocellular Carcinoma Development: Results of a Euro-Asian Survey. Journal of Infectious Diseases, 2000, 181, 1138-1142.	1.9	35
277	Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study11Data management by Italian Trials in Medical Oncology (I.T.M.O.) Scientific Service.. International Journal of Radiation Oncology Biology Physics, 1999, 45, 285-289.	0.4	56
278	RECURRENCE OF DESMOID TUMOR IN A MULTIVISCERAL TRANSPLANT PATIENT WITH GARDNER'S SYNDROME. Transplantation, 1999, 67, 1197-1199.	0.5	15
279	Increased Retinol Binding Protein in the Sera of Patients with Severe Ischemic Damage of the Liver after Transplantation. Clinical Biochemistry, 1998, 31, 113-116.	0.8	3
280	Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 29-34.	2.0	137
281	Effect of liver transplantation in cirrhotic diabetic patients. Transplantation Proceedings, 1998, 30, 1868.	0.3	2
282	Bone Lesion in a Patient with Transplanted Liver for a Metastatic Carcinoid. The Role of Somatostatin Receptor Scintigraphy. Tumori, 1998, 84, 82-84.	0.6	5
283	Spontaneous hypoglycaemia after pancreas transplantation in Type 1 diabetes mellitus. , 1998, 15, 991.		1
284	Hepatocellular carcinoma in patients who undergo liver transplantation: sensitivity of CT with iodized oil.. Radiology, 1997, 203, 457-460.	3.6	55
285	Renal-splenic shunt for infrahepatic caval occlusion after piggy-back liver transplantation. Transplant International, 1997, 10, 392-394.	0.8	3
286	Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplantation Proceedings, 1997, 29, 519-521.	0.3	92
287	Renal-splenic shunt for intrahepatic caval occlusion after piggy-back liver transplantation. Transplant International, 1997, 10, 392-394.	0.8	3
288	Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma. Journal of Viral Hepatitis, 1997, 4, 235-242.	1.0	6

#	ARTICLE	IF	CITATIONS
289	Metabolic effects of liver transplantation in cirrhotic patients.. Journal of Clinical Investigation, 1997, 99, 692-700.	3.9	45
290	Regulation of glucose homeostasis in humans with denervated livers.. Journal of Clinical Investigation, 1997, 100, 931-941.	3.9	95
291	Psychosocial adaptation after liver transplantation with particularreference to recipients aware of their cancer. European Journal of Surgical Oncology, 1996, 22, 240-244.	0.5	4
292	Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. New England Journal of Medicine, 1996, 334, 693-700.	13.9	6,573
293	The Role of Somatostatin Analogues in the Treatment of Gastro-Enteropancreatic Endocrine Tumours. Digestion, 1996, 57, 72-76.	1.2	14
294	Carcinoid syndrome. Pediatric Surgery International, 1996, 11, 398-399.	0.6	0
295	Risk of HBV reinfection after liver transplantation in HBsAgâ€positive cirrhosis: Primary hepatocellular carcinoma is not a predictor for HBV recurrence. Liver, 1996, 16, 117-122.	0.1	22
296	Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus.. Journal of Clinical Investigation, 1996, 97, 2611-2618.	3.9	63
297	A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Annals of Oncology, 1995, 6, 77-79.	0.6	82
298	Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression. Transplant International, 1994, 7, 409-411.	0.8	4
299	Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation.. Radiology, 1994, 192, 687-690.	3.6	92
300	Immunocytochemical Detection and Characterization of Intrahepatic Human Pancreatic Islets after Combined Liver-Islet Allograft Transplantation. Cell Transplantation, 1994, 3, 499-508.	1.2	12
301	Milan multicenter experience in liver transplantation for hepatitis C-related cirrhosis: report of 105 cases. Transplantation Proceedings, 1994, 26, 3582-4.	0.3	4
302	Hepatic resection for hepatocellular carcinoma. Journal of Surgical Oncology, 1993, 53, 62-66.	0.8	6
303	Reappraisal of the role of liver transplantation in the treatment of hepatocellular carcinoma arising in cirrhosis. Journal of Surgical Oncology, 1993, 53, 83-86.	0.8	3
304	Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: The experience of the National Cancer Institute of Milan. Annals of Oncology, 1993, 4, 489-493.	0.6	15
305	Confirmation of graft-versus-host disease after liver transplantation by PCR HLA-typing. Transplantation, 1993, 55, 423-5.	0.5	8
306	HEPATOTROPIC EFFECTS OF FK506 IN DOGS. Transplantation, 1991, 51, 67-69.	0.5	82

#	ARTICLE	IF	CITATIONS
307	Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1303-1308.	1.1	49
308	Further steps of hepatic stimulatory substance purification. <i>Digestive Diseases and Sciences</i> , 1991, 36, 674-680.	1.1	28
309	Cyclosporine and liver regeneration studied by in vivo <sup>31</sup> P nuclear magnetic resonance spectroscopy. <i>Digestive Diseases and Sciences</i> , 1991, 36, 687-692.	1.1	3
310	Role of estrogens and epidermal growth factor in hepatocellular carcinoma (HCC). <i>Digestive Diseases and Sciences</i> , 1991, 36, 1299-1302.	1.1	6
311	Effect of cyclosporine on hepatic energy status and on fructose metabolism after portacaval shunt in dog as monitored by phosphorus-31 nuclear magnetic resonance spectroscopy in vivo. <i>Hepatology</i> , 1991, 13, 780-785.	3.6	7
312	CHILDBEARING AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1990, 49, 317-320.	0.5	112
313	Hormonal and enzymatic parameters of hepatic regeneration in patients undergoing major liver resections. <i>Hepatology</i> , 1990, 12, 1134-1138.	3.6	58
314	A clinicopathologic study of primary hepatic carcinoid tumors. <i>Cancer</i> , 1990, 65, 1211-1218.	2.0	88
315	hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. <i>Cancer</i> , 1990, 66, 228-236.	2.0	26
316	Liver transplantation in patients with previous portasystemic shunt. <i>American Journal of Surgery</i> , 1990, 160, 111-116.	0.9	100
317	FK 506 as a growth control factor. <i>Transplantation Proceedings</i> , 1990, 22, 90-2.	0.3	26
318	Studies of the hepatotropic qualities of FK 506 and CyA. <i>Transplantation Proceedings</i> , 1990, 22, 93-5.	0.3	17
319	Reappraisal of surgical treatment of small hepatocellular carcinomas in cirrhosis: Clinicopathological study of resection or transplantation. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1571-1575.	1.1	31
320	Estradiol and testosterone levels in patients undergoing partial hepatectomy. <i>Digestive Diseases and Sciences</i> , 1989, 34, 818-822.	1.1	45
321	The effect of estrogen and tamoxifen on hepatocyte proliferation in Vivo and in Vitro. <i>Hepatology</i> , 1989, 9, 614-620.	3.6	136
322	A Modified Technique of Orthotopic Transplant of the Kidney in Rabbits. <i>Journal of Investigative Surgery</i> , 1989, 2, 293-303.	0.6	2
323	Efficacy of Liver Transplantation in Patients with Primary Biliary Cirrhosis. <i>New England Journal of Medicine</i> , 1989, 320, 1709-1713.	13.9	235
324	Pharmacologic Modulation of Experimental Postischemic Hepatic Function. <i>Annals of Surgery</i> , 1989, 209, 200-210.	2.1	34

#	ARTICLE	IF	CITATIONS
325	Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. <i>Surgery, Gynecology &amp; Obstetrics</i> , 1989, 168, 107-11.	0.6	68
326	Factors responsible for hepatic artery thrombosis after pediatric liver transplantation. <i>Transplantation Proceedings</i> , 1989, 21, 2466-7.	0.3	38
327	Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts. <i>Transplant International</i> , 1988, 1, 80-85.	0.8	14
328	Occurrence of cytomegalovirus hepatitis in liver transplant patients. <i>Journal of Medical Virology</i> , 1988, 24, 423-434.	2.5	59
329	Chordoma: Natural history and treatment results in 33 cases. <i>Journal of Surgical Oncology</i> , 1988, 37, 185-191.	0.8	143
330	Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts. <i>Transplant International</i> , 1988, 1, 80-85.	0.8	18
331	Primary lymphoma of the liver showing immunohistochemical evidence of T-cell origin. <i>Digestive Diseases and Sciences</i> , 1988, 33, 1632-1636.	1.1	30
332	Kaposi's sarcoma: Malignant tumor or proliferative disorder?. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 973-978.	0.9	12
333	Approach to Hepatic Metastases from Colorectal Adenocarcinoma. <i>Seminars in Liver Disease</i> , 1988, 8, 247-253.	1.8	2
334	Prolongation of Pig-to-Dog Renal Xenograft Survival by Modification of the Inflammatory Mediator Response. <i>Annals of Surgery</i> , 1987, 206, 482-495.	2.1	41